BSc, University of Alberta
PhD, University of Alberta
Postdoctoral Training, Duke University
A major research project in Professor Lee’s laboratory involves the use of viruses as anti-cancer agents. His team studies reovirus, a naturally occurring human virus that is undergoing phase I/II and III clinical trials internationally. Another project focuses on the tumor suppressor protein p53 and its link to Alzheimer’s Disease.
- Clements D, Sterea A, Kim Y, Helson E, Dean C, Nunokawa A, Coyle K, Shariff T, Marcato P, and Gujar S* and Lee P. 2015. Newly recruited CD11b+, GR-1+, Ly6Chigh myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus. Journal of Immunology. Mar 30. pii: 1402132. [Epub ahead of print] (*co-corresponding author).
- Garant K, Ahn D, Shmulevitz M, Pan L, Daigle RM, Gujar S* and Lee PWK. 2015. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. Accepted in Oncogene. (*co-corresponding author).
- Ahn D, Chisholm K, Pinto D, Sharif T, Gujar S* and Lee P. 2015. Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN response. Accepted in Cell Cycle. (*co-corresponding author).
- Gujar S, Clements D*, Delong R, Helson E, Marcato P and Lee P. 2014. Gemcitabine Potentiates Reovirus-induced Anti-Tumor Immune Activities and Enhances the Efficacy of Oncotherapy. British Journal of Cancer. 110:83-93. (*co-first author)
- View additional publications on PubMed
Selected awards and honours
- 2000 University of Alberta Alumni Honour Award
- 2002 Named “University Professor”, University of Calgary
- 2003 Celebration of Excellence Award, University of Calgary
- 2003-present Cameron Chair in Cancer Research, Dalhousie University
- 2010 Professional of Distinction Award: Discovery Centre for Science and Technology